Calcitriol Monotherapy for X-Linked Hypophosphatemia
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Children and adults with XLH recruited will be treated with calcitriol alone (without
phosphate supplementation) for one year, during which the calcitriol dose will be escalated
during the first 3 months of therapy. The investigators hypothesize that treatment of adults
and children with XLH alone will improve serum phosphate levels and skeletal mineralization
without causing an increase in kidney calcifications. The study will also examine if
calcitriol therapy will improve growth in children.
Phase:
Early Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)